Big Pharma battle threatens to delay Pacific trade pact

March 10, 2013 by Martin Abbugao

A US-led Pacific free trade pact faces further delays as a row between Big Pharma and activists supporting access to generic drugs erupts ahead of an October deadline, officials say.

Negotiators from the United States and 10 other countries are holding closed-door talks in Singapore from March 4-13 on the proposed Trans-Pacific Partnership (TPP) as they race to seal an accord.

"It's getting tougher and more challenging towards the end. There might be some problems in meeting that deadline, October 2013," Malaysian Trade Minister Mustapa Mohamed told the Foreign Correspondents Association of Singapore after the talks opened.

Activists pushing for greater public access to cheap generics are sparring with the pharmaceuticals industry, which was worth $355 billion in 2010 among the 11 countries involved in the talks, with US firms accounting for 80 percent of the market.

The dispute illustrates the complexity of the TPP, which has already missed a 2012 deadline due to differences over non-tariff issues like labour standards, environment protection, government procurement and .

Some countries are also keen to impose protection for sensitive sectors like agriculture and cars.

On pharmaceuticals, humanitarian group Medicins Sans Frontieres (Doctors Without Borders) asked negotiators from developing countries to reject what it claimed are patent provisions being pushed by Washington restricting access to .

MSF cited what it said was a leaked draft of the US negotiating position threatening to keep "monopoly protections that keep medicine prices high".

It warned that if other countries in the Asia-Pacific region eventually opt into the TPP, tighter may make out of reach to a wider number of people.

US President has mooted the TPP as a centrepiece of renewed American engagement in Asia.

The talks currently involve Australia, Brunei, Canada, Chile, Malaysia, Mexico, New Zealand, Peru, Singapore and Vietnam.

Japan has said it wants to join the process, but is expected to face strong domestic opposition against opening up its farm sector.

China is not involved in the talks, preferring to concentrate on other Asian trade pacts that analysts say require less stringent commitments.

MSF said one provision advocated by US negotiators in the TPP is the grant of new 20-year patents for modifications of existing medicines, making it harder to make cheaper generic versions.

Another provision makes it "more expensive and cumbersome to challenge" invalid patents, while another would add more years to a patent term to compensate for administrative processes, MSF added.

Pharmaceutical companies argue that copyright protections are necessary to allow them to recover investments and continue research on new cures.

The Pharmaceutical Research and Manufacturers of America (PhRMA), which sent representatives to monitor the Singapore talks, urged negotiators to adopt robust intellectual property (IP) protections.

"A weak IP framework within TPP would create uncertainty at a time when we need to be doing more to champion researchers and innovators who rely on strong protections," said Jay Taylor, PhRMA vice president of international affairs.

Taylor told AFP that PhRMA wants a provision that will give companies 12 years of data protection on new "biologic" medicines, which are made with living tissues in contrast to drugs made by compounding chemicals.

They are already being used to treat cancer and diabetes and are crucial in developing new cures, he said.

The 12-year protection should start from the time the new medicine is approved by regulators for release into the market, he said.

Taylor added that it takes an average of 10-13 years and more than $1.0 billion in investments to develop a new cure, but not all research projects are successful and some could lead to financial losses.

Medicine patents currently last 20 years, but Taylor said that research and development eat up more than half of the period as the coverage starts from the time the molecule is identified.

Explore further: India patent case threatens cheap drug supply: MSF

Related Stories

India patent case threatens cheap drug supply: MSF

September 5, 2011
Supply of cheap, copycat drugs for the developing world could be badly threatened if Swiss firm Novartis wins a challenge to India's patent law, medical charity MSF said on Monday.

India's global pharmacy role threatened by EU pact

February 10, 2012
(AP) -- Efforts by India and the European Union to strengthen trade are threatening India's ability to deliver lifesaving medicines to the world's poorest, analysts say as the two sides push through protracted negotiations ...

Novartis fights patent rejection in Indian court

September 6, 2011
(AP) -- In a case that could affect India's role as drug provider to the developing world, the Supreme Court began hearing arguments Tuesday over whether the government had the right to deny a patent to Swiss drugmaker Novartis ...

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Mar 10, 2013
I see the Evergreening of patented drugs is being pushed by the big pharma's. Its a scam to extend a patent by adding an inconsequential additive to the current formula making it appear like a new drug but ITS NOT! Its just a method to increase "the big rip-off". The India idea of a "Drug patent commons" is the best way to go. Every drug company can make any new drug but for the first 20 years the "inventor company" gets a percentage of all sales of the drug. They get their money for inventing the product and the consumer can actually afford the product. That makes more sense than huge profits and high expense as the current scenario provides. Big Pharma = Big lobbyist and resulting Big Profits. Welcome to free enterprise US style.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.